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Case Report
Cutaneous Metastasis as a complication of
hepatic intra-arterial chemotherapy
S O'Hagan, T Diamond
Accepted 9 June 1997
We report an unusual complication of hepatic
intra-arterial chemotherapy for metastatic
colorectal carcinoma.
CASE REPORT
A 44 year old man who had a resection for an
adenocarcinoma of the tranverse colon was also
foundtohave ametastatic noduleintherightlobe
of the liver (segment VI). He underwent a
laparotomy, during which an intra-operative
ultrasound revealed 2 additional nodules - in
segments IV and VII. These three lesions were
resected, each with 2 cm margin ofnormal liver.
A Portacath (Pharmacia Deltic/NC, St Paul
MN55112, USA) was inserted into the gastro-
duodenalartery. Aregimeofhepaticintra-arterial
chemotherapy was commenced post-operatively
with seven doses of 5-Fluorouracil (5-FU)
(500mg/M2per day) and one dose of Mitomycin
C (5mg/M2) on the first post-operative day. He
was subsequently given seven cycles of 5-FU
(400mg/M2 intravenous bolus followed by the
same dose in an intravenous infusion over 18
hours on days 1 and 2 of the cycle) and folinic
acid (200mg/M2 intravenous infusion, also on
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Figure Cutaneous metastasis surrounding Portacath
chamber.
days 1 and2). Eachcycle'sduration was 2weeks.
One year later he developed further hepatic
metastases. Six months after this he requested
removal of the Portacath due to abdominal
discomfort. Examination revealed a hard mass
around the Portacath (figure). This was removed
with the Portacath. Histological examination
identified an adenocarcinoma. The patient died
two months after the removal of the Portacath.
DISCUSSION
Treatment of hepatic metastases from primary
colorectal carcinoma remains problematic.
Hepatic resection mayofferincreased survival in
up to a quarter of patients but is usually only
practicable in those with less than four small
metastases. The role of chemotherapy for
advanced colorectal cancer is still controversial.
Due to the toxic side-effects of systemic
chemotherapy, hepatic intra-arterial infusions are
being explored as an alternative. The theoretical
reasons that HIA infusions may be successful are
thathepaticmetastases lessthan3 mmindiameter
derive theirblood supply fromthe hepatic artery.
HIA administered radiolabelled floxuridine
concen-trates in hepatic metastases to a much
greater degree than when systemically
administered and the high first pass metabolism
of certain agents prevents them from causing
systemic side effects.'
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HIA may delivered in several ways: angio-
graphically-placed hepatic arterial catheters,
surgically-implanted infusion ports used with
external pumps, or surgically-implanted silicone
catheters with subcutaneous chambers
(Portacath). HIA infusion is associated with
severalpotentialcomplications. Hepatic enzyme
elevation is quite common and stricturing ofthe
bile ducts, requiring stenting, may occur. Peptic
ulceration can occur and prophylactic proton
pump inhibitors should be used. Technical
difficulties in placing the catheter correctly and
occlusionofthehepatic arteryhavebeenreported.
However the systemic complications of 5-FU
treatment are largely avoided.2'3
The development of a metastastic lesion at the
subcutaneousinsertionoftheHIAinfusionsystem
has not been previously reported. We postulate
that the nodule may have arisen from peritoneal
disease which progressed along the catheter. In
this patient it was a late occurrence, but a rare
complication such as this may become more
common if HIA infusion becomes widely used
for the treatment of hepatic metastases.
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